Filtered By:
Specialty: Cardiology
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 478 results found since Jan 2013.

Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
Non-vitamin K antagonist oral anticoagulants (NOACs) are frequently used to prevent stroke in patients with atrial fibrillation. These patients are often also on aspirin or other antiplatelet agents. It is possible that treatment with both NOACs and aspirin or other antiplatelet drug may be effective in decreasing stroke, but data are sparse regarding the efficacy and safety of using both agents for stroke prevention. To address these issues, data were pooled from the 4 recent randomized, controlled trials of NOACs: apixaban, rivaroxaban, dabigatran, and edoxaban, which included 42,411 patients; 14,148 (33.4%) were also on...
Source: Cardiology in Review - August 9, 2016 Category: Cardiology Tags: Review Articles Source Type: research

Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation
Conclusions Rivaroxaban and dabigatran demonstrated better persistence than VKA at Day 360. Furthermore, rivaroxaban was associated with better persistence and adherence than dabigatran. Further studies are needed to identify factors responsible for this difference and evaluate the impact on outcomes.
Source: Europace - August 4, 2016 Category: Cardiology Authors: Beyer-Westendorf, J., Ehlken, B., Evers, T. Tags: Atrial fibrillation Source Type: research

Comparison of Dabigatran versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial.
CONCLUSIONS: -The presence of any VHD did not influence the comparison of dabigatran with warfarin. Clinical Trial Registration-URL: http://clinicaltrials.gov. Unique Identifier: NCT00262600. PMID: 27496855 [PubMed - as supplied by publisher]
Source: Circulation - August 4, 2016 Category: Cardiology Authors: Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L Tags: Circulation Source Type: research

Design and Rationale of the RE ‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of stent thrombosis and coronary events. Triple antithrombotic therapy, typically comprising warfarin, aspirin, and clopidogrel, is associated with a high risk of bleeding. A modest‐sized trial of oral anticoagulation with warfarin and clopidogrel without aspirin showed improvements in both bleeding and thrombotic events compared with triple therapy, but large trials are lacking. The RE‐DUAL PCI trial (NCT...
Source: Clinical Cardiology - July 31, 2016 Category: Cardiology Authors: Christopher P. Cannon, Savion Gropper, Deepak L. Bhatt, Stephen G. Ellis, Takeshi Kimura, Gregory Y.H. Lip, Ph. Gabriel Steg, Jurri ën M. Berg, Jenny Manassie, Jörg Kreuzer, Jon Blatchford, Joseph M. Massaro, Martina Brueckmann, Ernesto Ferreiros Ripoll Tags: Trial Designs Source Type: research

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.
Authors: Mezue K, Obiagwu C, John J, Sharma A, Yang F, Shani J Abstract Almost 800,000 new or recurrent strokes happen every year. Atrial fibrillation, the most common cardiac arrhythmia, is a major risk factor for stroke, accounting for 15-20% of ischemic strokes. Apixaban is a direct inhibitor of Factor Xa that was approved in December 2012 by the US Food and Drug Administration (FDA) for the prevention of stroke in patients with non-valvular atrial fibrillation. It is part of a family of novel oral anticoagulants (NOACs) which have the advantage over warfarin of less dosing variability, rapid onset of action and...
Source: Current Cardiology Reviews - July 29, 2016 Category: Cardiology Tags: Curr Cardiol Rev Source Type: research

Current Prescribing Trends for Atrial Fibrillation Anticoagulation in Australia
Introduction: Management of stroke risk in atrial fibrillation has changed over the last few years with the introduction of novel oral anticoagulants (NOACs) such as Apixaban, Rivaroxaban and Dabigatran. These agents are being increasingly prescribed secondary to the ease of use compared to warfarin which requires regular and ongoing INR monitoring.
Source: Heart, Lung and Circulation - July 27, 2016 Category: Cardiology Authors: D. Pol, V. Mutha, L. Bittinger Tags: 297 Source Type: research

Trends in Prescription of Novel Oral Anticoagulants (NOACs) and Warfarin in Australia 2010-2015
This study examines the rates of prescription of rivaroxaban, apixaban, dabigatran and warfarin over the period of July 2010 to June 2015.
Source: Heart, Lung and Circulation - July 27, 2016 Category: Cardiology Authors: A. Vlachadis Castles, I. Tsay, W. van Gaal Tags: 321 Source Type: research

Current Prescribing Trends for Atrial Fibrillation Anticoagulation in Australia
Introduction: Management of stroke risk in atrial fibrillation has changed over the last few years with the introduction of novel oral anticoagulants (NOACs) such as Apixaban, Rivaroxaban and Dabigatran. These agents are being increasingly prescribed secondary to the ease of use compared to warfarin which requires regular and ongoing INR monitoring.
Source: Heart, Lung and Circulation - July 26, 2016 Category: Cardiology Authors: D. Pol, V. Mutha, L. Bittinger Tags: 297 Source Type: research

Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin
Abstract The presence of spontaneous echo contrast (SEC) in the left atrium has been reported to be an independent predictor of thromboembolic risk in patients with atrial fibrillation (AF). Dabigatran was associated with lower rates of stroke and systemic embolism as compared with warfarin when administered at a higher dose. Between July 2011 and October 2015, nonvalvular AF patients treated with warfarin or dabigatran who had transesophageal echocardiography prior to ablation therapy for AF were enrolled. The intensity of SEC was classified into four grades, from 0 to 3. Univariate and multivariate analysis was ...
Source: Heart and Vessels - July 11, 2016 Category: Cardiology Source Type: research

Newer Oral Anticoagulants: Stroke Prevention and Pitfalls.
Authors: Patel A, Goddeau RP, Henninger N Abstract Warfarin is very effective in preventing stroke in patients with atrial fibrillation. However, its use is limited due to fear of hemorrhagic complications, unpredictable anticoagulant effects related to multiple drug interactions and dietary restrictions, a narrow therapeutic window, frequent difficulty maintaining the anticoagulant effect within a narrow therapeutic window, and the need for inconvenient monitoring. Several newer oral anticoagulants have been approved for primary and secondary prevention of stroke in patients with non-valvular atrial fibrillation. ...
Source: Open Cardiovascular Medicine Journal - June 29, 2016 Category: Cardiology Tags: Open Cardiovasc Med J Source Type: research

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation
Conclusion Annualized rates of all outcomes were constant with better efficacy of D150, less major bleeding with D110, and low intracerebral haemorrhage rates for both doses. There were no additional safety concerns. This is the longest continuous randomized experience of a novel anticoagulant.
Source: Europace - June 28, 2016 Category: Cardiology Authors: Ezekowitz, M. D., Eikelboom, J., Oldgren, J., Reilly, P. A., Brueckmann, M., Kent, A. P., Pogue, J., Spahr, J., Clemens, A., Noack, H., Diener, H.-C., Wallentin, L., Yusuf, S., Connolly, S. J. Tags: Atrial fibrillation Source Type: research

Cost-effectiveness Modelling of Novel Oral Anticoagulants Incorporating Real-world Elderly Patients with Atrial Fibrillation
Novel oral anticoagulants (NOACs) expand the treatment options for patients with atrial fibrillation (AF). Their benefits need to be weighed against the risk-benefit ratio in real-world elderly patients, prompting this cost-effectiveness study of NOACs (apixaban, dabigatran, edoxaban and rivaroxaban), warfarin and aspirin for stroke prevention in AF.
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Ying Jiao Zhao, Liang Lin, Hui Jun Zhou, Keng Teng Tan, Aik Phon Chew, Chee Guan Foo, Chia Theng Daniel Oh, Boon Peng Lim, Wee Shiong Lim Source Type: research

Dabigatran in clinical practice: Contemporary overview of the evidence
Oral anticoagulation is the cornerstone of stroke prevention in non-valvular atrial fibrillation (AF) and management of venous thromboembolism (VTE), resulting in a reduction in thrombotic complications and mortality. Benefit of vitamin K antagonists (VKAs) in such patients has been unambiguously confirmed, but VKA use is complicated by need for regular monitoring of the international normalized ratio and multiple drug and food interactions.Dabigatran is an oral direct thrombin inhibitor that can be used with fixed doses, without the need for routine anticoagulation laboratory monitoring and the advantage of few drug or diet interactions.
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Walter Ageno, John Eikelboom, Gregory Y.H. Lip Source Type: research

Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL Original Article
Conclusions— Using data from the PROTECT AF trial, LAA closure with the Watchman device was cost effective; using PREVAIL trial data, Watchman was more costly and less effective than warfarin and dabigatran. PROTECT AF enrolled more patients and has substantially longer follow-up time, allowing greater statistical certainty with the cost-effectiveness results. However, longer-term trial results and postmarketing surveillance of major adverse events will be vital to determining the value of the Watchman in clinical practice.
Source: Circulation: Arrhythmia and Electrophysiology - June 14, 2016 Category: Cardiology Authors: Freeman, J. V., Hutton, D. W., Barnes, G. D., Zhu, R. P., Owens, D. K., Garber, A. M., Go, A. S., Hlatky, M. A., Heidenreich, P. A., Wang, P. J., Al-Ahmad, A., Turakhia, M. P. Tags: Arrhythmias, Atrial Fibrillation, Anticoagulants, Treatment Original Article Source Type: research